The United States Food and Drug Administration (USFDA) has concluded inspection at AuroPeptides, a manufacturer of Peptide APIs, a subsidiary/business arm of Aurobindo Pharma, with one observation, relating to facility and equipment maintenance. This observation does not pertain to data integrity or related GMP compliance.
The USFDA conducted inspection at AuroPeptides from August 17 to 21, 2026. AuroPeptides is located at Indrakaran Village, Sangareddy District, Telangana.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
